ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Saturday, November 12, 2022

3:00PM-4:30PM: Abstract Number: 0514

Renal Response Outcomes of North American Youth with Proliferative Lupus Nephritis Treated with the EuroLupus versus NIH Cyclophosphamide Dosing Regimen

Abstracts: Pediatric Rheumatology – Clinical I: Connective Tissue Disease

3:00PM-4:30PM: Abstract Number: 0527

Rituximab as Maintenance Therapy for ANCA-associated Vasculitides: Pooled Analysis and Long-term Outcome of MAINRITSAN Trials

Abstracts: Vasculitis – ANCA-Associated

3:00PM-4:30PM: Abstract Number: 0511

SARS-CoV-2 mRNA Vaccine Immunogenicity in Chronic Inflammatory Arthritis on DMARD Therapy

Abstracts: Miscellaneous Rheumatic and Inflammatory Diseases I

3:00PM-4:00PM: Abstract Number: 0501

Single-molecule Spatial Transcriptomic Analysis Reveals Distinct Cellular Networks in Rheumatoid Arthritis Synovia

Abstracts: RA – Etiology and Pathogenesis

3:00PM-4:00PM: Abstract Number: 0500

T Cell and Macrophage Synergy Drive Inflammatory Synovial Fibroblasts in Rheumatoid but Not Psoriatic Arthritis

Abstracts: RA – Etiology and Pathogenesis

3:00PM-4:30PM: Abstract Number: 0513

The Association Between Age of Diagnosis and Disease Characteristics and Damage in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Abstracts: Pediatric Rheumatology – Clinical I: Connective Tissue Disease

3:00PM-4:30PM: Abstract Number: 0523

The Development of the Ranked Composite Important Difference in Diffuse Cutaneous Systemic Sclerosis; A Clinical and Patient Meaningful Anchor to the ACR-Composite Response Index in SSc

Abstracts: Systemic Sclerosis and Related Disorders – Clinical I: Trials and Therapeutics

3:00PM-4:00PM: Abstract Number: 0502

The Effect of Osteoporosis on Developing Vertebral Compression Fracture After Single-level Posterior Lumbar Fusion Surgery: A Large Healthcare Claims Database Study

Abstracts: Orthopedics, Low Back Pain, and Rehabilitation

3:00PM-4:00PM: Abstract Number: 0503

The Effect of Social Isolation on 1-Year Outcomes After Surgical Repair of Low Trauma Hip Fracture

Abstracts: Orthopedics, Low Back Pain, and Rehabilitation

3:00PM-4:00PM: Abstract Number: 0504

Three-dimensional Ground Reaction Force Symmetry Metrics Largely Fail to Explain Cartilage Worsening in the Contralateral Knee in Persons with Unilateral Knee Osteoarthritis: The Multicenter Osteoarthritis Study

Abstracts: Orthopedics, Low Back Pain, and Rehabilitation

4:30PM-6:00PM: Abstract Number: 0530

Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study)

Abstracts: RA – Diagnosis, Manifestations, and Outcomes I: Pre- and Early Disease

4:30PM-6:00PM: Abstract Number: 0543

An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis

Abstracts: Spondyloarthritis Including PsA – Treatment I: Axial Spondyloarthritis

4:30PM-6:00PM: Abstract Number: 0542

ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis: 2022 Update

Abstracts: Spondyloarthritis Including PsA – Treatment I: Axial Spondyloarthritis

4:30PM-6:00PM: Abstract Number: 0544

Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study

Abstracts: Spondyloarthritis Including PsA – Treatment I: Axial Spondyloarthritis

4:30PM-6:00PM: Abstract Number: 0539

Cardiac Complications, Thrombosis, Infections and All-cause Mortality Among Patients with End-Stage Kidney Disease Due to Lupus Nephritis in the USRDS 2006-2013 According to SLE Medication Use

Abstracts: SLE – Diagnosis, Manifestations, and Outcomes I: Renal Aspects

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].